---
figid: PMC7961479__cancers-13-01115-g001
figtitle: Predominant signaling pathways contributing to melanomagenesis and progression
organisms:
- Homo sapiens
- Mus musculus
- Canis lupus familiaris
- Lareunionomyces loeiensis
organisms_ner:
- Mus musculus
- Homo sapiens
- Canis lupus familiaris
- Drosophila melanogaster
pmcid: PMC7961479
filename: cancers-13-01115-g001.jpg
figlink: pmc/articles/PMC7961479/figure/cancers-13-01115-f001/
number: F1
caption: Predominant signaling pathways contributing to melanomagenesis and progression.
  Phosphorylation of receptor tyrosine kinases mesenchymal epithelial transition factor
  (c-MET), receptor-tyrosine kinase Kit (c-KIT) and vascular endothelial growth factor
  receptor (VEGFR) initiates signaling pathways resulting in proliferation, survival,
  motility, and angiogenesis. Activating mutations in downstream pathway components,
  such as reticular activating system (RAS), rapidly accelerated fibrosarcoma (RAF),
  and mitogen-activated protein kinase (MEK), confer constitutive pathway activation
  despite absence of growth signals [,,]. Activation of epithelial mesenchymal transition
  (EMT) has been implicated in acquired resistance to multiple drugs that target aberrant
  signaling.
papertitle: Resistance to Molecularly Targeted Therapies in Melanoma.
reftext: Meet Patel, et al. Cancers (Basel). 2021 Mar;13(5):1115.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9526056
figid_alias: PMC7961479__F1
figtype: Figure
redirect_from: /figures/PMC7961479__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7961479__cancers-13-01115-g001.html
  '@type': Dataset
  description: Predominant signaling pathways contributing to melanomagenesis and
    progression. Phosphorylation of receptor tyrosine kinases mesenchymal epithelial
    transition factor (c-MET), receptor-tyrosine kinase Kit (c-KIT) and vascular endothelial
    growth factor receptor (VEGFR) initiates signaling pathways resulting in proliferation,
    survival, motility, and angiogenesis. Activating mutations in downstream pathway
    components, such as reticular activating system (RAS), rapidly accelerated fibrosarcoma
    (RAF), and mitogen-activated protein kinase (MEK), confer constitutive pathway
    activation despite absence of growth signals [,,]. Activation of epithelial mesenchymal
    transition (EMT) has been implicated in acquired resistance to multiple drugs
    that target aberrant signaling.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Kitl
  - Vegfa
  - Kit
  - Hspg2
  - Pik3r1
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Tsc2
  - Slc12a3
  - Tsc22d1
  - Rheb
  - Ephb2
  - Mapk1
  - Mtor
  - Rps6kb1
  - KITLG
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - KDR
  - FLT1
  - FLT4
  - KIT
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - TSC2
  - SLC12A3
  - TSC1
  - TESC
  - RHEB
  - RHEBP1
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - RPS6KB1
  - scf
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - norpA
  - sl
  - Plc21C
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Ras64B
  - Ras85D
  - hop
  - bsk
  - Raf
  - Stat92E
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - gig
  - Tsc
  - Tsc1
  - Erk7
  - rl
  - Tor
  - S6k
  - Imatinib
  - Vemurafenib
  - O
  - Dabrafenib
  - MEKPF Trametinib
  - Selumetinib
---
